<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03316482</url>
  </required_header>
  <id_info>
    <org_study_id>LEUPLIN3M</org_study_id>
    <nct_id>NCT03316482</nct_id>
  </id_info>
  <brief_title>Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty</brief_title>
  <official_title>A Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jin Soon Hwang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, open-label, prospective study to evaluate the safety and efficacy of
      leuprorelin acetate DPS (Leuplin DPS) treatment quarterly in patients with central precocious
      puberty
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2015</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Leuprorelin treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage(%) of subjects with inhibition of LH response (peak &lt;3mIU/mL) maintained upon GnRH stimulation test</measure>
    <time_frame>at 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage(%) of subjects with a LH peak/FSH ratio maintained to be &lt;1 upon GnRH stimulation test at 12, 24, and 48 weeks</measure>
    <time_frame>at 12, 24, and 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Central Precocious Puberty</condition>
  <arm_group>
    <arm_group_label>Leuplin DPS 11.25mg s.c. every 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuplin DPS 11.25mg</intervention_name>
    <description>Leuplin DPS 11.25mg s.c. every 12 weeks</description>
    <arm_group_label>Leuplin DPS 11.25mg s.c. every 12 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female children aged '≥ 4 years ~ &lt; 9 years (8 years plus 364 days)

          2. Those who fall under Tanner stage 2 at least (on condition that they started to have
             breast budding under the age of 8)

          3. Female children who showed pubertal LH response to GnRH stimulation test (peak ≥
             7mIU/mL)

          4. Those whose bone age increased by one year or more compared to their chronological age

          5. Subjects and their guardians who gave written consent to participate in this study

        Exclusion Criteria:

          1. Those whose bone age is 11 years and 6 months or older

          2. Those secreting gonadal or adrenal cortex sex hormones in a non-LH-dependent manner

          3. Those who have anaphylaxis to the IP or synthetic LHRH, or LHRH derivative

          4. Those who have received GnRH analog treatment

          5. Those who require treatment likely to influence the hypothalamic-pituitary-gonadal
             axis during the study period

          6. Those receiving growth hormone

          7. Those who are suspected of or diagnosed with malignant tumor

          8. Patients with severe renal failure or hepatic failure, whose participation in this
             study is impossible in the investigator's opinion

          9. Those who have been administered one of the following drugs within 2 weeks before they
             started to participate in this study, or who are expected to be administered during
             the study period

               -  Estrogens

               -  Antiestrogens

               -  Progesterones

               -  Steroids

               -  Oriental medicines

         10. Those who have participated in another clinical study within 90 days from the date
             when the IP was administered

         11. Those who are found to be ineligible for this study in the investigator's opinion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Soon Hwang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajoun university hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Soon Hwang, MD, PhD</last_name>
    <phone>+82-10-4720-6852</phone>
    <email>pedhwang@ajou.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hwang, Jin Soon</name>
      <address>
        <city>Suwon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Soon Hwang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jin Soon Hwang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puberty, Precocious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

